Trial Profile
Clinical Study of Anlotinib With Temozolomide for Patients With Recurrent Glioblastoma
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 05 Feb 2020 New trial record